

A decorative vertical pattern of interconnected hexagons in light blue, running down the left side of the page.

Background • Bendamustine, an ancient alkylating agent developed more than 50 years ago, recently found its way back to the front scene of malignant hematology with impressive results demonstrated in chronic lymphocytic leukemia (CLL), indolent non-Hodgkin's lymphoma (NHL) including mantle-cell lymphoma, multiple myeloma and even aggressive NHL.

Methods • So far, we reviewed 34 unselected patients treated with bendamustine in a real-life setting. The patients' files were analyzed and data regarding indications for bendamustine, dosage and administration of this drug as well as response to treatment, progression-free survival (PFS) and overall survival (OS) were recorded. The final results will be revealed live at the Forum de Recherche en Oncologie (FRON) 2016.

Keywords: bendamustine; chronic lymphocytic leukemia, non-Hodgkin's lymphoma; multiple myeloma

*Department of
Hematology-Oncology
Saint-Joseph University
Beirut, Lebanon

